NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $5.02 -0.06 (-1.18%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.92▼$5.1250-Day Range$5.02▼$6.3452-Week Range$3.30▼$6.75Volume469,217 shsAverage Volume1.48 million shsMarket Capitalization$292.15 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Vanda Pharmaceuticals alerts: Email Address Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.0% Upside$13.00 Price TargetShort InterestBearish5.71% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment-0.01Based on 3 Articles This WeekInsider TradingSelling Shares$13,326 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.49) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector200th out of 910 stocksPharmaceutical Preparations Industry82nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingVanda Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.71% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 13.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 1.1 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vanda Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,326.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.49) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -62.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -62.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesSeptember 6 at 2:21 AM | americanbankingnews.comStockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)September 4, 2024 | prnewswire.comVanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment ConferenceSeptember 8, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 30, 2024 | americanbankingnews.comVanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.comAugust 29, 2024 | prnewswire.comVanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare ConferenceAugust 8, 2024 | seekingalpha.comVanda Pharmaceuticals: I Believe That The Bidding War Is Not OverAugust 1, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | gurufocus.comQ2 2024 Vanda Pharmaceuticals Inc Earnings Call TranscriptSeptember 8, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 1, 2024 | gurufocus.comVanda Pharmaceuticals Inc (VNDA) Q2 2024 Earnings Call Transcript Highlights: Revenue Growth ...July 31, 2024 | gurufocus.comVanda Pharmaceuticals Inc. Q2 2024 Earnings: EPS of -$0.08, Revenue of $50.5M Beats EstimatesJuly 31, 2024 | msn.comVanda Pharmaceuticals GAAP EPS of -$0.08 beats by $0.13, revenue of $50.5M beats by $2.64MJuly 31, 2024 | prnewswire.comVanda Pharmaceuticals Reports Second Quarter 2024 Financial ResultsJuly 31, 2024 | markets.businessinsider.comVanda Pharmaceuticals is about to announce its earnings — here's what to expectJuly 26, 2024 | prnewswire.comVanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024July 1, 2024 | prnewswire.comFederal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and ApotexJune 26, 2024 | reuters.comFuture Pak withdraws offer to buy Vanda PharmaceuticalsJune 26, 2024 | businesswire.comFuture Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.See More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/08/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+159.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.51 million Net Margins-6.00% Pretax Margin-6.57% Return on Equity-2.01% Return on Assets-1.68% Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.67 Sales & Book Value Annual Sales$182.02 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value$9.31 per share Price / Book0.54Miscellaneous Outstanding Shares58,198,000Free Float53,717,000Market Cap$292.15 million OptionableOptionable Beta0.77 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 64)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Timothy Williams (Age 48)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 58)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Scott L. HowellChief People OfficerKey CompetitorsGossamer BioNASDAQ:GOSSAkouosNASDAQ:AKUSAlbireo PharmaNASDAQ:ALBOAnaptysBioNASDAQ:ANABOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 580,265 shares on 8/20/2024Ownership: 2.734%Susquehanna Fundamental Investments LLCBought 5,994 shares on 8/15/2024Ownership: 0.494%AQR Capital Management LLCBought 48,945 shares on 8/15/2024Ownership: 0.130%Mackenzie Financial CorpSold 4,027 shares on 8/15/2024Ownership: 0.019%ProShare Advisors LLCSold 3,022 shares on 8/14/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $4.22 on January 1st, 2024. Since then, VNDA shares have increased by 19.0% and is now trading at $5.02. View the best growth stocks for 2024 here. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The biopharmaceutical company had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative trailing twelve-month return on equity of 2.01%. What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Vanda Pharmaceuticals' major shareholders? Top institutional shareholders of Vanda Pharmaceuticals include Renaissance Technologies LLC (7.06%), Dimensional Fund Advisors LP (3.45%), Acadian Asset Management LLC (3.41%) and Nantahala Capital Management LLC (2.73%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Timothy Williams, Richard W Dugan, Stephen Ray Mitchell and Aranthan Jones II. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL) and Sangamo Therapeutics (SGMO). This page (NASDAQ:VNDA) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredAmerica dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the...Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.